As SCLC rarely harbors BRCA1/2 mutations [45], the laboratory and clinical findings point to a potentially dominant role of SLFN11 in IIQ sensitivity even in the context of MYC amplification and BRCA proficiency. The gene discussed is SLFN11; the disease is small cell lung carcinoma.